<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704365</url>
  </required_header>
  <id_info>
    <org_study_id>NVX757.201</org_study_id>
    <nct_id>NCT01704365</nct_id>
  </id_info>
  <brief_title>RSV-F Vaccine Dose Ranging Study in Young Women</brief_title>
  <official_title>A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein
      nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groups</measure>
    <time_frame>Day 0 to Day 112</time_frame>
    <description>Immunogenicity will be measured using derived / calculated endpoints based on:
Geometric mean titer (GMT)
Geometric mean ratio (GMR)
Seroconversion rate (SCR)
Seroresponse rate (SRR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the safety</measure>
    <time_frame>Day 0 to Day 182</time_frame>
    <description>Number (and percentage) of subjects with solicited local and systemic Adverse Events over the seven days post-injections; all adverse events, solicited and unsolicited over 56 days post-first injection.
Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for six months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity based on neturalizing antibody titer</measure>
    <time_frame>Day 0 to Day 112</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 &amp; Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Day 0 and Day 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose RSV-F Vaccine with Adjuvant</intervention_name>
    <description>0.5mL IM Injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose RSV-F Vaccine without Adjuvant</intervention_name>
    <description>0.5ml IM Injection</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose RSV-F Vaccine with Adjuvant</intervention_name>
    <description>0.5mL IM Injection</description>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose RSV-F Vaccine without Adjuvant</intervention_name>
    <description>0.5mL IM Injection</description>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]</intervention_name>
    <description>0.5mL IM Injection</description>
    <arm_group_label>Group J</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5mL IM Injection</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult females, ≥ 18 and ≤ 35 years of age. &quot;Healthy&quot; shall be defined by the
             absence of any illness, acute or chronic, that requires ongoing systemic therapy for
             the control of symptoms or prevention of disability.

          -  Subjects on stable (no change in ≥ 3 months) therapy for findings (e.g., hypertension
             or hyperlipidemia) that are not associated with symptoms or disability are eligible,
             as are users of hormonal contraceptives.

          -  Subjects who receive intermittent prophylaxis for risks associated with asymptomatic
             findings (e.g., antibiotic prophylaxis prior to dental procedures in a subject with
             mitral valve prolapse) are eligible.

          -  Ongoing therapy will be defined as continuous or, if intermittent, more frequent than
             once every 3 months (e.g., use of an inhaled bronchodilator for exercise-induced
             bronchospasm more than once every 3 months). Immunosuppressives are subject to
             exclusion criterion #5 below.

          -  Persons being treated for illnesses or conditions that would become acutely
             symptomatic or disabling in the absence of treatment are not eligible.

          -  Willing and able to give informed consent prior to study enrollment.

          -  Able to comply with study requirements.

          -  Women who are not surgically sterile must have a negative urine pregnancy test prior
             to each vaccination; will be advised through the Informed Consent process to avoid
             becoming pregnant over the duration of the study, and must assert that they will
             employ an effective form of birth control for the duration of the study. Acceptable
             forms of birth control are: credible history of continuous abstinence from
             heterosexual activity, hormonal contraceptives (oral, injectable, implant, patch,
             ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and IUD.

        Exclusion Criteria:

          -  Participation in research involving investigational product (drug / biologic / device)
             within 45 days before planned date of first vaccination.

          -  History of a serious reaction to any prior vaccination.

          -  Received any vaccine in the 4 weeks preceding the study vaccination; or any RSV
             vaccine at any time.

          -  Any known or suspected immunosuppressive condition, acquired or congenital, as
             determined by history and/or physical examination.

          -  Chronic administration (defined as more than 14 continuous days) of immunosuppressants
             or other immune-modifying drugs within 6 months prior to the administration of the
             study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a
             systemic dose ≥10mg of prednisone per day or equivalent. The use of topical, inhaled,
             and nasal glucocorticoids will be permitted.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the study vaccine or during the study.

          -  Acute disease at the time of enrollment (defined as the presence of a moderate or
             severe illness with or without fever, or an oral temperature &gt;38.0°C on the planned
             day of vaccine administration).

          -  Known disturbance of coagulation.

          -  Women who are pregnant or breastfeeding, or plan to become pregnant during the study.

          -  Suspicion or recent history (within one year of planned vaccination) of alcohol or
             other substance abuse.

          -  Any condition that in the opinion of the investigator would pose a health risk to the
             subject if enrolled or could interfere with evaluation of the vaccine or
             interpretation of study results (including neurologic or psychiatric conditions deemed
             likely to impair the quality of safety reporting).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Nigel Thomas, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novavax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance Rockville</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novavax.com</url>
    <description>Novavax Homepage</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <disposition_first_submitted>February 5, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 7, 2014</disposition_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

